Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease

Chong, Jimmy; Karner, Charlotta; Poole, Phillippa

doi:10.1002/14651858.cd009157.pub2

Cited by 74 publications

(56 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a systematic review of seven randomised trials that directly compared a LAMA (i.e. tiotropium) with LABAs, meta-analyses found that the LAMA had a greater effect on reducing COPD exacerbations, exacerbation-related hospitalisations, and adverse effects, but there were no differences in mortality, all-cause hospitalisations, symptoms, or lung function [131].…”

Section: Standard Pharmacological Therapiesmentioning

confidence: 99%

An official American Thoracic Society/European Respiratory Society statement: research questions in COPD

et al. 2015

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity, mortality, and resource use worldwide. The goal of this official American Thoracic Society (ATS)/European Respiratory Society (ERS) research statement is to describe evidence related to diagnosis, assessment and management; identify gaps in knowledge; and make recommendations for future research. It is not intended to provide clinical practice recommendations on COPD diagnosis and management.Clinicians, researchers, and patient advocates with expertise in COPD were invited to participate. A literature search of Medline was performed, and studies deemed relevant were selected. The search was not a systematic review of the evidence. Existing evidence was appraised and summarised, and then salient knowledge gaps were identified.Recommendations for research that addresses important gaps in the evidence in all areas of COPD were formulated via discussion and consensus.Great strides have been made in the diagnosis, assessment and management of COPD, as well as understanding its pathogenesis. Despite this, many important questions remain unanswered. This ATS/ ERS research statement highlights the types of research that leading clinicians, researchers, and patient advocates believe will have the greatest impact on patient-centred outcomes. @ERSpublications ATS/ERS statement: which types of research will have the greatest future impact on patientcentred outcomes in COPD? http://ow.ly/I54Hb

show abstract

Section: Standard Pharmacological Therapiesmentioning

confidence: 99%

An official American Thoracic Society/European Respiratory Society statement: research questions in COPD

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Moreover, according to the results of many studies, tiotropium shows an equivalent effect with long-acting β 2 agonists in many parameters, such as the rates of hospitalization and pulmonary functions and the improvement of symptoms in COPD treatment (16).…”

Section: Discussionmentioning

confidence: 99%

The Effects of Budesonid That Added to Tiotropium Therapy on Health Related Quality of Life, Exercise Capacity and Pulmonary Functions in COPD Patients

Arslan¹,

Turgut²

2015

Eurasian J Pulmonol

View full text Add to dashboard Cite

Objective: The aim of this study was to evaluate the effects of adding inhaled budesonide to the tiotropium treatment on the pulmonary function tests, health-related quality of life and exercise capacity of patients with chronic obstructive pulmonary disease (COPD). Methods:Forty study subjects with COPD were randomized to two groups. The patients in the first group was treated with 1x1 18 mcg of Tiotropium and the patients in the second group was treated with the combination of tiotropium (18 mcg 1x1) and budesonide (400 mcg 2x1) for three months. Pulmonary function tests, six minute walk test, body mass index and Saint George Respiratory Questionnaire (SGRQ) scores were recorded both at the beginning and 3 months later and the results at the begining and third month were compared with each other. There were no statistically significant difference in all basline parameters between the two groups. Results:At the end of the study, no statistically significant differences were obtained between two groups in terms of pulmonary function tests (p>0.05). Significant improvements were observed on the parameters of walking distance (p=0.023) and SGRQ scores (symptom score: p<0.001, activity score: p=0.001, impact score: p=0.003 and total score: p<0.001) in Group 2 when compared with Group 1. Conclusion:These results show that, in patients with COPD, tiotropium/budesonide combination is more effective than alone tiotropium inhalation in quality of life and exercise performance. But this combination is not more effective in improving lung functions.

show abstract

“…In a systematic review of seven randomised trials that directly compared a LAMA (i.e. tiotropium) with LABAs, meta-analyses found that the LAMA had a greater effect on reducing COPD exacerbations, exacerbation-related hospitalisations and adverse effects, but there were no differences in mortality, all-cause hospitalisations, symptoms or lung function [89]. The meta-analyses were limited by heterogeneity, suggesting that the differences between the LAMA and LABAs may have been due to the specific LABA (i.e.…”

Section: Standard Pharmacological Therapiesmentioning

confidence: 99%

An official American Thoracic Society/European Respiratory Society statement: research questions in COPD

et al. 2015

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity, mortality and resource use worldwide. The goal of this official American Thoracic Society (ATS)/European Respiratory Society (ERS) Research Statement is to describe evidence related to diagnosis, assessment, and management; identify gaps in knowledge; and make recommendations for future research. It is not intended to provide clinical practice recommendations on COPD diagnosis and management.Clinicians, researchers and patient advocates with expertise in COPD were invited to participate. A literature search of Medline was performed, and studies deemed relevant were selected. The search was not a systematic review of the evidence. Existing evidence was appraised and summarised, and then salient knowledge gaps were identified.Recommendations for research that addresses important gaps in the evidence in all areas of COPD were formulated via discussion and consensus.Great strides have been made in the diagnosis, assessment and management of COPD, as well as understanding its pathogenesis. Despite this, many important questions remain unanswered. This ATS/ ERS research statement highlights the types of research that leading clinicians, researchers and patient advocates believe will have the greatest impact on patient-centred outcomes. @ERSpublications ATS/ERS statement highlighting research areas that will have the greatest impact on patientcentred outcomes in COPD

show abstract

Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease

Cited by 74 publications

References 92 publications

An official American Thoracic Society/European Respiratory Society statement: research questions in COPD

An official American Thoracic Society/European Respiratory Society statement: research questions in COPD

The Effects of Budesonid That Added to Tiotropium Therapy on Health Related Quality of Life, Exercise Capacity and Pulmonary Functions in COPD Patients

An official American Thoracic Society/European Respiratory Society statement: research questions in COPD

Contact Info

Product

Resources

About